To the ER? Can Patients Treat Their Anaphylaxis at Home?

IF 5.4 2区 医学 Q1 ALLERGY Current Allergy and Asthma Reports Pub Date : 2024-11-01 Epub Date: 2024-09-02 DOI:10.1007/s11882-024-01174-6
Marcus S Shaker, Aikaterini Anagnostou, Matthew Greenhawt
{"title":"To the ER? Can Patients Treat Their Anaphylaxis at Home?","authors":"Marcus S Shaker, Aikaterini Anagnostou, Matthew Greenhawt","doi":"10.1007/s11882-024-01174-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>To discuss if all patients who use self-injectable epinephrine outside the hospital setting require immediate emergency care.</p><p><strong>Recent findings: </strong>Prior to 2023, anaphylaxis management guidance universally recommended that patients who use self-injectable epinephrine outside of the hospital or clinic setting immediately activate emergency medical services and seek further care. Additional food-induced anaphylaxis management recommendations specified that all patients always carry 2 auto-injector devices and give a second dose of epinephrine if there was not immediate response within 5 min of injection. Patients presenting for emergency care after epinephrine are often observed for up to 4-6 h afterwards, even when completely asymptomatic. These management steps have lacked evidence for improving outcomes, and universal implementation of these approaches is not cost-effective as guidance for food allergic patients. Epinephrine pharmacokinetics and pharmacodynamics suggest that peak physiologic response is more likely to occur closer to 15 min than before 5 min, that few patients require a second dose of epinephrine as most stabilize within 15 min of use, that 60 min of observation after a patient stabilizes after epinephrine use may be adequate as patients infrequently have further sequelae, and that not everyone needs to carry 2 epinephrine auto-injectors on their person at all times. The most recent anaphylaxis practice parameter promotes a contextualized approach to these management questions, outlining the option for watchful waiting to gauge response to epinephrine before seeking emergency care, which has been proven as a more cost-effective management strategy. The recent updated anaphylaxis care guidelines support the evolution of anaphylaxis care, in that universal, immediate activation of emergency services is not required for using self-injectable epinephrine outside the hospital setting.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":" ","pages":"623-629"},"PeriodicalIF":5.4000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Allergy and Asthma Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11882-024-01174-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/2 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose of review: To discuss if all patients who use self-injectable epinephrine outside the hospital setting require immediate emergency care.

Recent findings: Prior to 2023, anaphylaxis management guidance universally recommended that patients who use self-injectable epinephrine outside of the hospital or clinic setting immediately activate emergency medical services and seek further care. Additional food-induced anaphylaxis management recommendations specified that all patients always carry 2 auto-injector devices and give a second dose of epinephrine if there was not immediate response within 5 min of injection. Patients presenting for emergency care after epinephrine are often observed for up to 4-6 h afterwards, even when completely asymptomatic. These management steps have lacked evidence for improving outcomes, and universal implementation of these approaches is not cost-effective as guidance for food allergic patients. Epinephrine pharmacokinetics and pharmacodynamics suggest that peak physiologic response is more likely to occur closer to 15 min than before 5 min, that few patients require a second dose of epinephrine as most stabilize within 15 min of use, that 60 min of observation after a patient stabilizes after epinephrine use may be adequate as patients infrequently have further sequelae, and that not everyone needs to carry 2 epinephrine auto-injectors on their person at all times. The most recent anaphylaxis practice parameter promotes a contextualized approach to these management questions, outlining the option for watchful waiting to gauge response to epinephrine before seeking emergency care, which has been proven as a more cost-effective management strategy. The recent updated anaphylaxis care guidelines support the evolution of anaphylaxis care, in that universal, immediate activation of emergency services is not required for using self-injectable epinephrine outside the hospital setting.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
去急诊室?患者可以在家治疗过敏性休克吗?
审查目的:讨论是否所有在医院外使用自我注射肾上腺素的患者都需要立即进行急救:在 2023 年之前,过敏性休克管理指南普遍建议在医院或诊所之外使用自我注射肾上腺素的患者立即启动紧急医疗服务并寻求进一步治疗。食物诱发的过敏性休克管理建议还规定,所有患者应始终携带两个自动注射器装置,如果在注射后 5 分钟内没有立即反应,则应注射第二剂肾上腺素。注射肾上腺素后急诊就医的患者通常需要观察长达 4-6 小时,甚至在完全无症状的情况下也是如此。这些管理步骤缺乏改善预后的证据,而且普遍采用这些方法作为食物过敏患者的指导并不划算。肾上腺素的药代动力学和药效学表明,生理反应峰值更有可能在接近 15 分钟时出现,而不是在 5 分钟之前;很少有患者需要使用第二剂肾上腺素,因为大多数患者会在使用后 15 分钟内病情稳定;在患者使用肾上腺素病情稳定后观察 60 分钟可能就足够了,因为患者很少会出现进一步的后遗症;并非每个人都需要随身携带 2 个肾上腺素自动注射器。最新的过敏性休克实践参数提倡根据具体情况来解决这些管理问题,概述了在寻求急救护理之前可选择观察等待,以评估对肾上腺素的反应,这已被证明是一种更具成本效益的管理策略。最近更新的过敏性休克护理指南支持过敏性休克护理的发展,即在医院外使用自我注射肾上腺素不需要立即普遍启动急救服务。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.20
自引率
1.80%
发文量
21
审稿时长
6-12 weeks
期刊介绍: The aim of Current Allergy and Asthma Reports is to systematically provide the views of highly selected experts on current advances in the fields of allergy and asthma and highlight the most important papers recently published. All reviews are intended to facilitate the understanding of new advances in science for better diagnosis, treatment, and prevention of allergy and asthma. We accomplish this aim by appointing international experts in major subject areas across the discipline to review select topics emphasizing recent developments and highlighting important new papers and emerging concepts. We also provide commentaries from well-known figures in the field, and an Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research. Over a one- to two-year period, readers are updated on all the major advances in allergy and asthma.
期刊最新文献
When the Nose Meets the Lab: Histopathological Analysis in Chronic Rhinosinusitis with Nasal Polyps for Routine Clinical Practice. Current Review of Comorbidities in Chronic Rhinosinusitis. Minimizing Indoor Allergen Exposure: What Works? Subcutaneous Immunotherapy of Food Allergy. To the ER? Can Patients Treat Their Anaphylaxis at Home?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1